Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMC03. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMC03 level relative to a control or a reference level that is normal or indicating favorable prognosis.